U.S. inflation data ahead; Trump nominates new BLS head - what’s moving markets
OXFORD, UK - Oxford Biomedica PLC (LSE:OXB), a leader in cell and gene therapy CDMO, disclosed today the grant of nil-cost share options to its executives under the company’s Long Term Incentive Plan (LTIP) and Deferred Bonus Plan (DBP).
The grants, issued on May 16, 2025, are part of the company’s strategy to align executive compensation with its growth targets. The Remuneration Committee has identified EBITDA margin and revenue growth as the key performance indicators for these awards.
Chief Executive Officer Frank Mathias received the highest number of share options, with a total of 350,204 granted under the LTIP and an additional 70,803 under the DBP. This increases his total held options to 1,001,298, representing 0.94% of the current issued share capital.
Other executives, including Chief Financial Officer Lucinda Crabtree, Group General Counsel Natalie Walter, and Chief Business Officer Sebestien Ribault, also received significant grants. The total number of options granted to the executives ranged from 9,780 to 350,204 shares.
The transaction took place outside of a trading venue and no consideration was paid for the grant of these awards. The specific targets for EBITDA margin and revenue growth related to the LTIP grants are detailed in the 2024 Directors’ Remuneration Report.
The share options are part of the company’s commitment to incentivize its top management in line with the company’s performance. The full details of the transactions are available in accordance with the EU Market Abuse Regulation.
This move underscores Oxford Biomedica’s focus on retaining and motivating key personnel through equity-based compensation, a common practice in the biotechnology industry. It is based on a press release statement issued by the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.